Advances in cytoreductive surgery and combination chemotherapy have improved 5-year survival in patients with epithelial ovarian cancer, but the rate of cure remains essentially unchanged over the last two decades. Computer models suggest that detection of ovarian cancer in early stage (I-II) could improve rates of cure by 10-30%. Sequential use of serum biomarkers measured over time followed by TVS in a small fraction of postmenopausal women with rising CA125 has proven more specific and more sensitive than either modality used alone. Using this strategy, the United Kingdom Collaborative Trial for Ovarian Cancer Screening (UKCTOCS) and the Normal Risk Ovarian Cancer Screening Study (NROSS) in the United States have shown that only 3 operations are required to detect each case of ovarian cancer. Over the last 13 years, our group has conducted the NROSS study in 4,904 postmenopausal women at average risk for ovarian cancer. Annual determinations of CA125 have been analyzed by the Risk of Ovarian Cancer Algorithm (ROCA) developed by Dr. Skates. If the risk does not change, women return in a year; if it increases markedly, TVS is performed and participants are referred to a gynecologic oncologist; if the risk is intermediate CA125 is repeated in 3 months. Fifteen operations have been performed to detect 10 ovarian cancers. Two were borderline tumors and 8 were invasive with 8 of the 10 (80%) in Stage I or II. The NROSS trial has utilized a well-coordinated network of 7 sites in the United States where 22,981 blood samples have been obtained, processed and stored with standard operating protocols. Pre-operative specimens from MDACC have been banked from 502 women with ovarian cancer and 737 with benign disease. This has provided a valuable resource for evaluating new biomarkers. As CA125 is expressed by only 80% of epithelial ovarian cancers, additional biomarkers will be required to optimize sensitivity. Our group has found that HE4 and CA72.4 can detect 16% of the cases missed by CA125 in samples from the UKCTOCS trial. Autoantibodies to tumor associated antigens have shown even greater promise. Elevated levels of autoantibodies against TP53 have been found in 20-25% of patients with normal CA125 at the time of conventional diagnosis. Titers of anti-TP53 rise 13.5 months (mean) prior to CA125 and 33 months (mean) prior to diagnosis in patients who present without an increase in CA125. At present we are developing a new ROCA that incorporates CA125, HE4, CA72.4 and anti-TP53 autoantibody data. A multidisciplinary team of 27 investigators will pursue the following Specific Aims: 1) to conduct a screening trial to determine the specificity and positive predictive value for a 4 biomarker ROCA including CA125, HE4, CA72.4 and anti-TP53 autoantibodies in a two stage strategy for early detection of ovarian cancer in postmenopausal women at average risk for the disease; 2) to maintain and share a serum and plasma bank to facilitate evaluation of novel biomarkers for early detection; 3) to collaborate with other Centers in the EDRN to evaluate additional biomarkers for early detection of ovarian cancer.

Public Health Relevance

When ovarian cancer is diagnosed at an early stage, combination surgery and chemotherapy can cure 90% of women with disease contained in the ovary (stage I) and 70% with disease limited to the pelvis (stage II), but when disease has spread further, cure slips to 20% or less. Our group has shown that annual measurement of CA125 followed by ultrasound, and surgery, if indicated, can detect early stage (I, II) disease with no more than three operations for each case detected. Our Clinical Validation Center will provide specimens to EDRN Biomarker Validation Laboratories and test whether annual measurement of four blood tests detects early stage cases with an acceptable number of benign ovarian lesions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA200462-03
Application #
9458134
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Patriotis, Christos F
Project Start
2016-05-05
Project End
2021-03-31
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Hospitals
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yang, Wei-Lei; Lu, Zhen; Bast Jr, Robert C (2017) The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn 17:577-591
Mathieu, Kelsey B; Bedi, Deepak G; Thrower, Sara L et al. (2017) Screening for ovarian cancer: imaging challenges and opportunities for improvement. Ultrasound Obstet Gynecol :
Yang, Wei-Lei; Gentry-Maharaj, Aleksandra; Simmons, Archana et al. (2017) Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Clin Cancer Res 23:5912-5922